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Abstract
Mitochondrial dysfunction has been implicated in multiple neurodegenerative diseases but remains largely
unexplored in Creutzfeldt-Jakob disease. Here, we characterize the mitochondrial respiratory chain at the individual
neuron level in the MM1 and VV2 common molecular subtypes of sporadic Creutzfeldt-Jakob disease. Moreover, we
investigate the associations between the mitochondrial respiratory chain and neuropathological markers of the
disease.
Brain tissue from individuals with sporadic Creutzfeldt-Jakob disease and age-matched controls were obtained from
the brain collection of the Austrian Creutzfeldt-Jakob Surveillance. The mitochondrial respiratory chain was studied
through a dichotomous approach of immunoreactivities in the temporal cortex and the hippocampal subregions of
CA4 and CA3.
We show that profound deficiency of all mitochondrial respiratory complexes (I-V) occurs in neurons of the severely
affected temporal cortex of patients with Creutzfeldt-Jakob disease. This deficiency correlates strongly with the
severity of neuropathological changes, including vacuolation of the neuropil, gliosis and disease associated prion
protein load. Respiratory chain deficiency is less pronounced in hippocampal CA4 and CA3 regions compared to
the temporal cortex. In both areas respiratory chain deficiency shows a predilection for the MM1 molecular subtype
of Creutzfeldt-Jakob disease.
Our findings indicate that aberrant mitochondrial respiration could be involved early in the pathogenesis of
sporadic Creutzfeldt-Jakob disease and contributes to neuronal death, most likely via ATP depletion. Based on these
results, we propose that the restricted MRI diffusion profile seen in the brain of patients with sporadic Creutzfeldt-
Jakob disease might reflect cytotoxic changes due to neuronal respiratory chain failure and ATP loss.
Keywords: Mitochondria, Respiratory chain, Prion, Neurodegeneration, PrP
© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: gabor.kovacs@uhnresearch.ca; gabor.kovacs@utoronto.ca;
charalampos.tzoulis@nevro.uib.no; charalampos.tzoulis@helse-bergen.no
†Gabor G. Kovacs and Charalampos Tzoulis contributed equally to this work.
3Institute of Neurology, Medical University of Vienna, Vienna, Austria
1Neuro-SysMed, Department of Neurology, Haukeland University Hospital,
5021 Bergen, Norway
Full list of author information is available at the end of the article
Flønes et al. Acta Neuropathologica Communications            (2020) 8:50 
https://doi.org/10.1186/s40478-020-00915-8
Introduction
Sporadic Creutzfeldt-Jakob disease (sCJD) is a severe and
lethal neurodegenerative disease that commonly manifests
between the sixth and seventh decade of life with an over-
all incidence of 1–2 /million / year [1]. While it is most
often recognized by rapidly progressive dementia and
myoclonus, it has a broad spectrum of clinical presenta-
tions including ataxia, visual disturbances, tremor and
other movement disorders. The neuropathology of sCJD
is characterized by neuronal loss, vacuolation of the
neuropil, reactive gliosis and disease-associated prion pro-
tein (PrPsc) deposits [2]. PrPsc are pathological aggrega-
tions of prion protein (PrPc), a naturally occurring protein
of unclear physiological function encoded by the PRNP
gene. sCJD differs from other neurodegenerative proteino-
pathies in that self-aggregating PrPsc is considered to be
the primary disease-causing event, and that it is transmis-
sible through nerve to nerve contact [1]. PrPsc aggregation
is disease specific and is found both in subtle synaptic and
perineuronal accumulations and more granular, periva-
cuolar and plaque-like accumulations depending on dis-
ease subtype [2]. PrPsc has been shown to exist in
molecular subtypes that show differences in size and de-
gree of glycosylation, degree of protease resistance, aggre-
gation state and conformational stability; namely PrPsc
type 1 and 2 [3, 4].
Clinical and pathological features of sCJD are strongly
influenced by the molecular subtype of PrPsc and the
genotype of codon 129 of the PRNP gene, coding for ei-
ther methionine or valine [2, 5]. Individuals who are
homozygous for the methionine codon (MM) and have
type 1 PrPsc (MM1) typically develop rapidly progressive
dementia and myoclonus. Pathological examination com-
monly shows involvement of neocortex, striatum and thal-
amus, while the hippocampus and brain stem are
relatively spared [4]. Individuals who are homozygous for
the valine codon (VV) and have type 2 PrPsc (VV2) often
present with ataxia and develop dementia at later stages.
Pathologically, individuals with VV2 show involvement of
the deep neocortical layers, subcortical nuclei and the hip-
pocampal formation [4].
Mitochondrial dysfunction, including mitochondrial re-
spiratory chain (MRC) deficiency and mitochondrial DNA
(mtDNA) damage, has been implicated in multiple neuro-
degenerative diseases [6], but has not been as extensively
explored in sCJD. Mitochondrial abnormalities, including
morphological alterations, MRC deficiency and impaired
mitochondrial dynamics have been reported by studies in
cell- and animal models of prion disease [7–10]. Further-
more, one study indicated decreased RNA and protein ex-
pression levels for several MRC subunits in human bulk
brain tissue [11]. However, since disease-associated
changes in cell-type composition have been shown to con-
found mitochondrial measurements in bulk brain tissue
[12, 13], it is unknown to what degree the reported find-
ings reflected MRC depletion in individual cells, or altered
cell composition in the CJD samples. While decreased im-
munofluorescent staining for subunits of complexes I, IV
and V was also observed in sCJD [11], this has not been
systematically studied. Thus, the question of whether ab-
errant mitochondrial function occurs within neurons of
the sCJD brain remains largely unexplored.
In this work, we study the MRC complexes in single
neurons of severely and mildly affected regions in the
brain of individuals with either MM1 or VV2 molecular
subtypes of sCJD. Our findings show that there is defi-
ciency of all MRC complexes in the temporal cortex of
sCJD. Interestingly, MRC deficiency has a predilection for
the MM1 molecular subtype of sCJD and is strongly asso-
ciated with neuropathological markers of the disease.
Material and methods
Patient cohorts and tissue samples
Brain tissue from individuals with sCJD (n = 20) and
controls (n = 6) was obtained from the brain collection
of the Austrian Creutzfeldt-Jakob Surveillance at the In-
stitute of Neurology, Medical University of Vienna. We
chose to study two regions showing different patho-
logical involvement in sCJD: (i) the temporal cortex,
which is severely affected, and (ii) the CA4 and CA3
subregions of the hippocampus, which are considered
relatively spared of neuropathological changes [14].
Brains were collected at autopsy and sampling was per-
formed as previously described [15]. All samples were
collected using a standard technique and a mean fixation
time of 30 days. Tissue with suspected prion disease was
treated in 98% formic acid (FA) for one hour prior to
paraffin embedding according to routine. Our material
includes three neurologically healthy controls (Ctrl), and
three disease-controls (CtrlD) in which CJD was initially
suspected but excluded after neuropathological examin-
ation. CtrlD showed signs of neurodegeneration includ-
ing senile neurodystrophic changes and chronic vascular
lesions, but an exact diagnosis was not available. CtrlD
were included to study the effect of FA treatment on the
tissue, as neurologically healthy controls had not been
FA treated. Individuals with sCJD were grouped accord-
ing to codon 129 polymorphism of the PRNP gene and
PrPsc type (nMM1 = 10, nVV2 = 10) based on neuropatho-
logical examination as previously described [16]. All in-
cluded individuals were examined by a neuropathologist
at autopsy and sections were stained with hematoxylin
and eosin using a standard protocol and with antibodies
against PrPsc (12F10sc, SPIbio #A03221, dilution 1:
2000). Sections were autoclaved at 121 °C for 10 min fol-
lowing 5 min treatment in concentrated FA and protein-
ase K. All sections were stained using the Autostainer
Link 48 by Agilent Dako. There was no difference in
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post-mortem delay, formalin fixation time or age be-
tween controls, and individuals with MM1- or VV2 mo-
lecular subtypes of sCJD. Furthermore, there was no
difference in the disease duration between individuals in
the MM1 and VV2 groups. Sex was not balanced be-
tween the controls (5 females and 1 male) and patients
(9 females and 11 males). As previous studies have not
shown gender-dependent differences in mitochondrial
staining [17], we deemed this acceptable.
Immunohistochemistry
Immunohistochemistry (IHC) for mitochondrial markers
was carried out on formalin-fixed, paraffin embedded
sections from the hippocampus and temporal cortex of
individuals with sCJD and controls (CtrlD and Ctrl). Ser-
ial sections with a thickness of 3 μm were deparaffinised
in xylene and rehydrated in graded ethanol. Antigen re-
trieval was performed in 1 mM EDTA at pH 8. All
sections were stained using Autostainer Link 48 by Agi-
lent Dako. Sections were blocked in peroxidase-blocking
solution. Primary antibodies (all from Abcam) against
MRC complexes; complex I (anti-NDUFB8, ab110242,
dilution 1: 4000), complex II (anti-SDHA, ab14715, dilu-
tion 1: 10,000), complex III (anti-UQCRC2, ab14745, di-
lution 1: 20,000), complex IV (anti-MTCO1, ab14705,
dilution 1: 20,000), complex V (anti-ATP5A, ab14748,
dilution 1: 20,000), and the mitochondrial membrane
marker VDAC1 (anti-VDAC1, ab14734, dilution 1: 20,
000) were diluted in EnVision™ FLEX Antibody Diluent
and were incubated at room temperature for 30 min.
HRP (horseradish peroxidase)-polymer and DAB (3,3′-
Diaminobenzidine) chromogen kits were used for
visualization. Peroxidase-blocking solution, TBST buffer,
mouse-linker, HRP-polymer and DAB chromogen were
all from Agilent (EnVision FLEX+, Mouse, High pH
(Link), K8002).
Fig. 1 Neuropathological evaluation of sCJD tissue. Representative examples of the neuropathological evaluation of our samples. (A-B) Gliosis (a)
and vacuolation (b) were scored based on hematoxylin and eosin stainings on a scale from no gliosis/vacuolation (0), to slight (1), moderate (2)
and severe (3) state. Scalebar: 50 μm. (c) Representative examples of PrPsc-immunoreactivity in a negative control (0), and individuals with MM1
type sCJD showing slight (1), moderate (2) and prominent (3) diffuse/synaptic immunoreactivity. Scale bar: 100 μm. (d-e) Neurons stained with
mitochondrial markers were dichotomized and labeled as positive (d) or deficient (negative and intermediate staining) (e)
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Immunohistochemistry analysis
Both FA treated and -untreated tissue was available from
the CtrlD-group, which allowed us to study the effect of
FA pretreatment in single individuals. Only the FA
treated sections were later included for comparisons be-
tween sCJD and the entire control group. To evaluate
the effect of FA treatment, tissue from the CtrlD-group
that had either been FA treated or not was analysed
using a semi-quantitative method to calculate the frac-
tion of positive pixels per neuron as previously described
[17]. All sections stained with antibodies against MRC
complexes or VDAC1 were analyzed visually and the
percentage of positive or deficient neurons was deter-
mined in the entire CA4, including the transition into
CA3, and in a 2.5 mm2 area in the temporal cortex in
close relation to the transition from entorhinal cortex
into the temporal cortex. Neurons were identified based
on morphology, and only neurons where the nucleus
and nucleolus were clearly visible were included. All sec-
tions were scanned using the NanoZoomer 2.0-HT
While Slide Imager (Hamamatsu), and image analyses
were conducted using the NDP.view2 (v2.7.25). Neurons
from the CA4/CA3 regions were evaluated at 20X mag-
nification, while neurons from the temporal cortex were
evaluated at 40X magnification.
Neuropathological assessment
Hippocampal sections stained with hematoxylin and
eosin (H&E) were scored with regard to gliosis and
vacuolation based on a scale from 0 (no astrocytic glio-
sis/vacuolation) to 3 (severe astrocytic gliosis/vacuol-
ation) as previously reported [5]. Reactive astrocytes
were identified from their typically swollen eosinophilic
cytoplasm. Only cells with a clearly visible nucleus were
evaluated. The neuropathological scoring was performed
by two investigators (IHF and GGK) and was done in a
region-specific manner resulting in one score from the
CA4 region and a separate score from the temporal cor-
tex. In addition, region-specific morphometric analysis
of immunoreactivity to PrPsc was calculated using Fiji
(v.2.0.0) [18]. For the morphometric analyses, single im-
ages from the regions of interest were deconvoluted
using the color deconvolution tool and an automatic
threshold was set using the Isodata threshold mode.
Next, all images were binarized and a fraction of mea-
sured pixels per image was used to give a score of per-
centage of PrPsc stain per image. The Isodata threshold
mode was chosen as it was the best fit for strongly and
intermediately stained images. Negative images were not
analyzed (n = 3 in the CA4 of the MM1 group) due to
an overestimation of immunoreactivity. Types of PrPsc
deposits were not considered in the analyses. However,
images from the temporal cortex were acquired in the
deeper cortical layers (5 and 6). All images were ac-
quired at 20X magnification. Examples of scores for the
neuropathological assessment are shown in Fig. 1.
Statistical analysis
Statistical analyses were performed in SPSS (v.25.0.0) and
Graphpad Prism (v7.0b). Clinical data were compared
using t-tests, unless the data were not normally distributed
in which case Mann-Whitney U-test was used. Normality
was tested using the Shapiro-Wilk test. Equality of vari-
ances was tested using Levene’s test. A one-way ANOVA
Fig. 2 Effect of formic acid treatment on immunohistochemistry. Formic acid treated (FA+) and untreated (FA-) tissue from disease-controls was
compared using two different approaches. Findings from analyses in the temporal cortex are shown. a Semi-quantification of neuronal
cytoplasmic stain, here exemplified by complex I (NDUFB8), shows less MRC deficiency in FA+ compared to FA- from the same three individuals.
b Visual analysis and categorization of the same sections and individuals resulted in more consistent results. % deficient cytoplasm: mean
percentage of neuronal unstained cytoplasm, % deficient neurons: percentage of total neurons from 2.5 mm2 of temporal cortex that did not
stain positive. Bars show mean and range
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was conducted between the groups (Ctrl, MM1 and VV2)
to test differences of means of the MRC complex analyses.
Due to the unequal sample sizes, the Welch’s test for
unequal variance was used. Eta squared (η2) was used to
determine effect size of any significant difference. Games-
Howell post hoc test was chosen to decide at what level
the groups were significantly different due to their un-
equal sample sizes and variance. The relationship between
neuropathology and MRC deficiency was assessed by pair-
wise Spearman’s correlations. Due to a small sample size,
correlations were studied in the entire sCJD group. A lin-
ear regression was performed to evaluate covariation be-
tween the molecular subtype of sCJD and vacuolation as a
marker of neuropathology. A P-value < 0.05 was consid-
ered statistically significant in all analyses. Data are pre-
sented as mean and 95% confidence interval (CI).
Results
Effect of formic acid treatment on immunohistochemistry
Using semi-quantification of unstained cytoplasm, we
found that FA treatment slightly skewed the measurements
towards less MRC deficiency compared to non-FA treated
tissue (Fig. 2a). To mitigate the confounder of FA treatment
effects on the tissue analyses, we chose instead a visual bin-
ary analysis approach to categorize each neuron as either
MRC positive or deficient. This approach produced sub-
stantially more consistent results between FA treated and
untreated tissues (Fig. 2b). Specifically, FA treatment had
no effect on the staining of VDAC1 or MRC complexes II,
III and V. For the MRC complexes I and IV FA treatment
had a minor effect on staining and was associated with a
slight underestimation of deficient neurons in FA-treated
tissue. Thus, FA treatment could potentially skew our re-
sults towards less deficient neurons for complexes I and IV
in sCJD. As a result of this, the reported deficiency of MRC
complexes I and IV in sCJD may be slightly underestimated
in this work.
Neuronal MRC deficiency in sCJD
To assess the MRC in the sCJD-brain, we performed
IHC for MRC complexes I-V in the CA4 region (Fig. 3)
and temporal cortex (Fig. 4) of sCJD patients and
Fig. 3 Mitochondrial respiratory chain deficiency in sCJD hippocampus (CA4). a Representative photographs of mitochondrial respiratory chain
complex stainings (complex I: NDUFB8, complex II: SDHA, complex III: UQCRC2, complex IV: MTCO1, complex V: ATP5A) and VDAC1 in the CA4 region
of controls (top row), sCJD molecular subtypes VV2 (middle row) and MM1 (lower row). Mitochondrial respiratory chain deficient neurons are visible in
both MM1 and VV2 (+: positive neurons, #: deficient neurons). Decreased staining is observed both in neurons and in surrounding neuropil. Scale bar:
100 μm. b Scatter plots showing the fraction of deficient neurons in the CA4 region of the hippocampus. Each dot represents the mean percentage
of deficient neurons for each respiratory complex per individual with sCJD (VV2 or MM1) or control. Bars show mean and 95%- confidence intervals]
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controls. VDAC1 was used as a marker for mitochondrial
mass. In the temporal cortex, sCJD patients had a signifi-
cantly higher fraction of MRC deficient neurons compared
to controls. Significant deficiency was found for all MRC
complexes (complex I; P = 0.001 η2 = 0.60, complex II; P =
0.001, η2 = 0.55, complex III; P = 0.003, η2 = 0.49, complex
IV; P = 0.001, η2 = 0.73, complex V; P = 0.003, η2 = 0.40). A
similar, but overall less pronounced deficiency was found
in the CA4/CA3 region (complex I; P = 0.006 η2 = 0.31,
complex II; P = 0.019, η2 = 0.20, complex III; P = 0.119,
complex IV; P = 0.040, η2 = 0.26, complex V; P = 0.003,
η2 = 0.33; Table 2). VDAC1 staining revealed no difference
in mitochondrial mass between groups in either region
(temporal cortex; P = 0.542, CA4/CA3; P = 0.621). The
total number of evaluated neurons in each group, means
with 95% CI and results of one way-ANOVA are summa-
rized in Table 2. As reflected in their means and 95% CI’s,
there was no difference in staining intensity of neither
mitochondrial marker nor MRC complexes between CtrlD
and Ctrl. Subject demographics of included individuals are
summarised in Table 1.
MRC deficiency is more pronounced in the MM1
molecular subtype of sCJD
Individual assessment of MM1- and VV2 sCJD molecu-
lar subtypes showed highly significant differences in
terms of MRC deficiency. Compared to controls, tissue
from MM1 molecular subtype of sCJD exhibited signifi-
cant deficiency of all MRC complexes in the temporal
cortex (complex I; P < 0.001, complex II; P = 0.001,
complex III; P = 0.005, complex IV; P < 0.001, complex
V; P = 0.007) and of complex I (P = 0.010) and complex
V (P = 0.034) in the CA4/CA3 region. MRC staining was
substantially less affected in VV2 molecular subtype of
sCJD. With the exception of mild complex V (P = 0.019)
deficiency in the CA4/CA3 region, neuronal MRC stain-
ing in the VV2 molecular subtype of sCJD was not sig-
nificantly different from controls (Table 2).
Complex I deficiency in the temporal cortex correlates
with sCJD neuropathology
Next, we sought to investigate whether the MRC defi-
ciency correlated with neuropathology markers of sCJD
Fig. 4 Mitochondrial respiratory chain deficiency in sCJD temporal cortex. a Representative photographs of mitochondrial respiratory chain
complexes I-V staining (complex I: NDUFB8, complex II: SDHA, complex III: UQCRC2, complex IV: MTCO1, complex V: ATP5A) and VDAC1 in the
temporal cortex of controls (top row), sCJD molecular subtypes VV2 (middle row) and MM1 (lower row). Evidence of MRC deficiency is observed
in both MM1 and VV2 (+: positive neurons, #: deficient neurons). Scale bar: 50 μm. b Scatter plots showing the fraction of deficient neurons in the
temporal cortex. Each dot represents the mean percentage of deficient neurons for each respiratory complex per individual with sCJD (VV2 or
MM1) or control. Bars show mean and 95% confidence intervals
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(Fig. 5). To this end, we chose complex I deficiency as a
representative marker of MRC deficiency. Individual
scores of neuropathology markers and means with 95%
CI are listed in Table 3. As expected, vacuolation and
PrPsc-staining correlated significantly with gliosis in all
examined areas (Fig. 5a). Intriguingly, in the temporal
cortex, we found a significant positive correlation be-
tween the amount of complex I deficient neurons and
vacuolation (P < 0.001, rs = 0.725), gliosis (P < 0.001, rs =
0.771) and PrPsc stain (P = 0.018, rs = 0.537; Fig. 5b). In
contrast, the hippocampal regions CA4/CA3 showed no
correlation with any of the neuropathology markers
(vacuolation; P = 0.699, gliosis; P = 0.605, PrPsc stain; P =
0.109; Fig. 5c). Disease duration did not correlate with
the percentage of complex I deficient neurons in either
temporal cortex (P = 0.227) or the CA4/CA3 hippocam-
pal regions (P = 0.951). Linear regression with vacuol-
ation as covariate confirmed that molecular subtype of
sCJD is a predictor of MRC deficiency (Beta = 0.40, P =
0.019), however, this difference could be partly
confounded by severity of vacuolation (Beta = 0.57, P =
0.002).
Discussion
We show that neuronal MRC deficiency affecting all re-
spiratory complexes occurs in the brain of patients with
sCJD. This deficiency shows a strong association with the
severity of pathological markers of disease and has a predi-
lection for the MM1 molecular disease subtype. In spite of
the pronounced MRC loss, the outer mitochondrial
Table 1 Demographic overview, post-mortem delays and fixation times of included samples
ID AOD Sex Molecular subtype DD (months) PMD (h) FT (days)
sCJD
sCJD1 62 F VV2 4 72 10
sCJD2 58 F VV2 7 24 46
sCJD3 61 M VV2 3 24 19
sCJD4 73 F VV2 4 48 31
sCJD5 69 M VV2 4 72 22
sCJD6 75 M VV2 6 24 18
sCJD7 62 M VV2 2 48 14
sCJD8 65 M VV2 6 72 21
sCJD9 75 M VV2 2 24 24
sCJD10 75 M VV2 8 24 17
sCJD11 80 F MM1 4 24 27
sCJD12 66 F MM1 6 96 3
sCJD13 74 F MM1 4 48 32
sCJD14 68 F MM1 3 24 44
sCJD15 72 F MM1 3 24 56
sCJD16 67 M MM1 6 48 112
sCJD17 69 M MM1 2 24 15
sCJD18 72 M MM1 6 < 24 16
sCJD19 80 F MM1 1.5 48 98
sCJD20 70 M MM1 8 24 30
CtrlD
Ctrl1 67 F – – 24 31
Ctrl2 78 F – – 48 14
Ctrl3 81 F – – 24 37
Ctrl
Ctrl4 65 F – – 24 20
Ctrl5 73 F – – 48 22
Ctrl6 81 M – – 24 15
CJD Sporadic Creutzfeldt-Jakob disease, CtrlD Disease-control, Ctrl Control, AOD Age of death, PMD Post-mortem delay (hours), FT Fixation time (days), F Female, M
Male, DD Disease duration in months
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membrane marker VDAC1 remains intact, indicating that
the total neuronal mitochondrial mass remains un-
changed. The finding of deficient MRC in sCJD corrobor-
ate the work of Ansoleaga et al., who reported deficiency
of multiple MRC complexes in the frontal cortex of MM1
type sCJD [11].
Neuronal MRC deficiency in sCJD shows a strong cor-
relation with the severity of the neurodegenerative





Mean (95% CI) ANOVA Welch (P =) η2 Group comparisons GH (P =)
CA4/CA3 VDAC1 Ctrl 1242 0 (0,0) 0.621 – Ctrl vs VV2 –
VV2 2404 0.06 (−0.07,0.19) Ctrl vs MM1 –
MM1 2411 0.08 (−0.04,0.19) MM1 vs VV2 –
NDUFB8 Ctrl 1442 5.76 (2.72, 8.80) 0.006 0.310 Ctrl vs VV2 0.302
VV2 2499 20.17 (− 0.32, 40.66) Ctrl vs MM1 0.010
MM1 2085 51.45 (24.51, 78.39) MM1 vs VV2 0.122
SDHA Ctrl 1194 0.61 (−0.30, 1.51) 0.019 0.195 Ctrl vs VV2 0.075
VV2 2052 5.58 (1.17, 9.99) Ctrl vs MM1 0.097
MM1 1878 15.55 (1.27, 29.83) MM1 vs VV2 0.325
UQCRC2 Ctrl 1381 0.26 (−0.07, 0.59) 0.119 – Ctrl vs VV2 –
VV2 1675 0.54 (−0.21, 1.29) Ctrl vs MM1 –
MM1 1913 9.28 (−0.14, 18.71) MM1 vs VV2 –
MTCO1 Ctrl 1282 2.18 (0.71, 3.64) 0.040 0.255 Ctrl vs VV2 0.373
VV2 2263 6.99 (−0.61, 14.58) Ctrl vs MM1 0.062
MM1 2000 27.52 (5.92, 49.12) MM1 vs VV2 0.151
ATP5A Ctrl 1252 0.37 (−0.57, 1.30) 0.003 0.331 Ctrl vs VV2 0.019
VV2 1803 4.01 (1.62, 6.40) Ctrl vs MM1 0.034
MM1 1554 20.96 (5.49,35.48) MM1 vs VV2 0.082
Temporal cortex VDAC1 Ctrl 1942 2.71 (−0.05, 5.46) 0.542 – Ctrl vs VV2 –
VV2 2876 6.10 (−0.09, 12.29) Ctrl vs MM1 –
MM1 2784 3.26 (−1.38, 7.89) MM1 vs VV2 –
NDUFB8 Ctrl 1275 6.82 (−0.31, 13.96) 0.001 0.603 Ctrl vs VV2 0.116
VV2 2116 27.68 (7.12, 48.25) Ctrl vs MM1 < 0.001
MM1 1633 67.50 (51.98, 83.01) MM1 vs VV2 0.008
SDHA Ctrl 1171 0.54 (−0.18, 1.25) 0.001 0.547 Ctrl vs VV2 0.071
VV2 1822 16.62 (2.47, 30.77) Ctrl vs MM1 0.001
MM1 1107 55.95 (34.93, 76.97) MM1 vs VV2 0.008
UQCRC2 Ctrl 1461 0.97 (−0.42, 2.36) 0.003 0.492 Ctrl vs VV2 0.278
VV2 1666 5.38 (−0.60, 11.37) Ctrl vs MM1 0.005
MM1 975 35.39 (17.23, 53.56) MM1 vs VV2 0.012
MTCO1 Ctrl 1237 6.31 (−1.12, 13.75) 0.001 0.727 Ctrl vs VV2 0.179
VV2 1895 14.18 (7.38, 20.97) Ctrl vs MM1 < 0.001
MM1 1515 58.60 (41.42, 75.77) MM1 vs VV2 0.001
ATP5A Ctrl 1758 1.78 (−1.57, 5.13) 0.003 0.404 Ctrl vs VV2 0.162
VV2 2034 16.92 (0.14, 33.70) Ctrl vs MM1 0.007
MM1 1127 50.57 (24.19, 76.94) MM1 vs VV2 0.066
The table summarizes results of one-way ANOVA and eta squared analysis of effect where a significant difference at the group level. 95% CI: 95% confidence
interval, η2; eta squared, GH: Games-Howell, Ctrl: control, MM1: MM1 molecular subtype of sCJD, VV2; VV2 molecular subtype of sCJD. Statistically significant P-
values are in bold type
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changes. It has a clear regional predilection for the se-
verely affected temporal cortex, whereas the relatively
spared CA4/CA3 hippocampal regions show only a mild
decrease in MRC staining. Moreover, the extent of MRC
deficiency in the temporal cortex shows a positive cor-
relation with the severity of neuropathological changes
including gliosis, vacuolation and PrPsc load. We believe
that the lack of association between MRC deficiency and
severity of neuropathology in the CA4/CA3 region may
reflect insufficient statistical power due to the substan-
tially milder MRC involvement in that area.
The severity of MRC deficiency is associated with the
molecular subtype of sCJD. MRC deficiency is significantly
more pronounced in neurons of individuals with MM1 type
sCJD compared to VV2 type sCJD. In fact, with the excep-
tion of complex V, MRC deficiency in VV2 type sCJD was
not statistically significant compared to controls, although a
trend was seen for higher numbers of MRC-deficient neu-
rons. Regression analysis shows that the difference between
molecular subtype of sCJD is partly confounded by the
more severe pathological changes in MM1 molecular
phenotype. Spongiform changes are more pronounced in
the neocortex of MM1 type sCJD compared to VV2, where
the basal ganglia and thalamus are predominantly affected
[19]. However, as disease subtype remains a significant pre-
dictor of MRC deficiency in our model, we cannot exclude
the possibility of additional factors rendering MM1 neurons
more susceptible to MRC impairment.
Fig. 5 Neuropathology correlates with complex I deficiency in the temporal cortex. Correlation plots of clinicopathological variables and MRC
deficiency, exemplified by complex I (NDUFB8). Vacuolation and PrPsc-immunoreactivity correlate with gliosis in CA4/CA3 and temporal cortex (a).
Vacuolation, gliosis and PrPsc-immunoreactivity correlate with mitochondrial complex I deficiency in the temporal cortex, (b) but not the
hippocampal regions of CA4/CA3 (c)
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Our findings suggest that MRC deficiency is an inte-
gral part of sCJD pathology and plays an important role
in the pathogenesis of the disorder. While MRC defi-
ciency correlates strongly with the severity of disease
specific pathological markers, the fact that it is also
present in morphologically normal neurons of the mildly
affected CA4/CA3 region suggests it is not a terminal
phenomenon in dying neuronal populations. The mech-
anisms underlying MRC loss in sCJD remain unknown.
Since mitochondrial mass is unchanged, it is possible
MRC is depleted via an active downregulation or in-
creased degradation of the peptide subunits of the
respiratory complexes. mtDNA encodes subunits of
complexes I, III, IV and V and quantitative and/or quali-
tative mtDNA defects are a common cause of MRC defi-
ciency [20]. However, mtDNA defects should not affect
complex II, which is entirely encoded in the nucleus,
and very rarely cause a uniform loss of the remaining re-
spiratory complexes. Therefore, the MRC deficiency of
sCJD does not fit the profile of pure mtDNA defects.
The observed pan-respiratory complex deficiency
without a change in the mitochondrial outer membrane
marker VDAC1 may reflect damage to the inner mito-
chondrial membrane. This is in line with previous
Table 3 Neuropathological assessments
CA4/CA3 Temporal
ID Type % PrP stain Gliosis Vacuo % PrP stain Gliosis Vacuo
sCJD
sCJD1 VV2 37.26 2 0 22.64 2 1
sCJD2 VV2 50.04 3 1 56.09 3 3
sCJD3 VV2 20.15 2 0 13.65 2 1
sCJD4 VV2 49.70 3 2 28.90 2 2
sCJD5 VV2 32.07 2 0 43.63 1 0
sCJD6 VV2 39.31 2 0 46.17 2 3
sCJD7 VV2 42.61 2 0 17.31 2 0
sCJD8 VV2 42.88 2 1 60.23 3 3
sCJD9 VV2 37.42 1 0 57.27 2 1
sCJD10 VV2 33.55 3 3 14.93 2 0
Mean (95% CI) 38.50 (32.19, 44.81) 2.20 (1.75, 2.65) 0.7 (−0.06, 1.46) 36.08 (22.75, 49.41) 2.10 (1.69, 2.51) 1.4 (0.50, 2.30)
sCJD11 MM1 – 2 0 34.13 3 3
sCJD12 MM1 18.16 1 0 53.85 2 2
sCJD13 MM1 – 0 0 41.26 2 2
sCJD14 MM1 18.17 2 1 61.81 3 3
sCJD15 MM1 20.25 2 0 59.89 3 3
sCJD16 MM1 – 1 0 40.80 3 2
sCJD17 MM1 21.99 0 0 18.50 1 1
sCJD18 MM1 29.68 2 1 58.40 3 2
sCJD19 MM1 21.48 2 0 29.17 2 2
sCJD20 MM1 19.43 1 0 57.80 3 3
Mean (95% CI) 21.31 (17.63, 24.99) 1.43 (0.70, 2.16) 0.29 (−0.17, 0.74) 48.49 (32.50, 64.48) 2.43 (1.70, 3.16) 2.29 (1.59, 2.98)
CtrlD
Ctrl1 – – 1 0 – 1 0
Ctrl2 – – 1 0 – 0 0
Ctrl3 – – 0 0 – 0 0
Ctrl
Ctrl4 – – 0 0 – 0 0
Ctrl5 – – 0 0 – 1 0
Ctrl6 – – 2 0 – 1 0
sCJD = sporadic Creutzfeldt-Jakob disease, CtrlD Diseased control, Ctrl Control, MM1 MM1 molecular subtype sCJD, VV2 VV2 molecular subtype sCJD, % PrP
stain = % morphometric score of prion stain, Gliosis = score gliosis, Vacuo = score vacuolation
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reports of abnormal mitochondrial cristae architecture
in prion infected rodents [8, 21, 22]. Interestingly, while
PrPc has been shown to localize mostly on the plasma
membrane, it has been suggested that it may also be
present in the inner mitochondrial membrane of healthy
mice [23]. Furthermore, dysmorphic mitochondria with
abnormal cristae morphology have been observed in
PRNP knockout mice [24]. It is therefore possible that
PrPsc aggregation injures the inner mitochondrial mem-
brane, both directly and via loss of its physiological
counterpart, PrPc.
Irrespective of the cause, deficiency of the entire MRC
is expected to compromise neuronal metabolism causing
ATP depletion and a shift toward increased glycolysis
[25]. Neurons are highly dependent on oxidative phos-
phorylation and use most of their ATP to maintain their
membrane potential. This is achieved via the action of the
sodium-potassium ATPase, which maintains the intra-
and extracellular concentrations of sodium and potassium
ions against their electrochemical gradients and, by exten-
sion, regulates intracellular water balance [26]. Pump fail-
ure due to ATP deficiency causes a shift of water from the
extracellular to the intracellular compartment (i.e. cyto-
toxic edema), leading to disruption of essential cellular
processes and ultimately cell death. In fact, diffusion
weighted imaging (DWI) of the brain typically shows evi-
dence of restricted water diffusion in affected areas of the
sCJD brain [27], suggesting that cytotoxic edema is indeed
an important mechanism underlying neuronal death in
sCJD. Based on our findings, we propose that cytotoxic
changes in the sCJD brain are caused by ATP depletion
due to neuronal MRC deficiency. Similar signs of re-
stricted water diffusion on MRI are seen in other disorders
involving neuronal energy failure such as mitochondrial
disease [28–30], hypoxia/ischemia [31], hypoglycaemia
[32, 33] and carbon monoxide intoxication [34].
Another consequence of neuronal MRC impairment in
sCJD would be a shift toward glycolytic metabolism,
resulting in higher production of lactate. Elevated con-
centration of cerebrospinal fluid (CSF) lactate has indeed
been reported in patients with CJD, corroborating this
hypothesis [35]. In addition to decreased ATP produc-
tion, a glycolytic shift could render neurons more sus-
ceptible to oxidative damage. Normally, neurons can
consume glucose through the pentose phosphate path-
way, which helps to regenerate reduced glutathione, an
important component against oxidative stress. Up-
regulation of glycolysis may therefore cause increased
levels of oxidized glutathione, in turn, increased suscep-
tibility to the formation of reactive oxygen species in
neurons [36]. Oxidative damage has indeed been impli-
cated in cell models of prion disease [37–39].
While cause and effect cannot be confidently dis-
cerned by this type of study, our findings strongly
suggest that MRC loss in sCJD is deleterious and actively
involved in the neurodegenerative process. Interestingly,
the pattern of MRC deficiency in sCJD is distinct from
that of other neurodegenerative proteinopathies. In Par-
kinson’s disease, MRC deficiency is selective for complex
I (and to a much lesser degree complex IV) and does
not correlate with the severity of neurodegeneration. In
fact, unlike sCJD where the load of PrPsc correlates with
MRC deficiency, in PD there is an inverse relationship
between complex I loss and Lewy pathology leading to
the hypothesis that it may be a partly protective event
[17, 40]. It is conceivable that downregulation of com-
plex I levels without a decrease in the remaining respira-
tory complexes, as observed in PD, serves to limit
reactive oxygen species (ROS) production and oxidative
damage without a major compromise in energy trans-
duction. In contrast, the global MRC loss seen in sCJD
is highly likely to cause ATP depletion.
In conclusion, we show that mitochondrial dysfunction
is an important mechanism underlying neuronal injury
and neurodegeneration in sCJD. These findings provide
an explanation for the clinical observations of restricted
MRI diffusion and elevated CSF lactate in patients. Our
findings suggest that mitochondria should be the focus
of further study in sCJD and should be assessed as po-
tential therapeutic targets for this incurable and devas-
tating disorder.
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